Basilea Pharmaceutica AG
BSLN | SW
Overview
Corporate Details
- ISIN(s):
- CH0011432447 (+1 more)
- LEI:
- 391200TTZP8EIPSJ5J20
- Country:
- Switzerland
- Address:
- Henric Petri-Strasse 35, 4051 Basel
- Website:
- https://www.basilea.com/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Basilea is a revenue-generating, commercial-stage Swiss biopharmaceutical company. Our activities are focused in the areas of hospital antibiotics, hospital antifungals and cancer treatments. Our portfolio comprises of two marketed anti-infective brands (Cresemba® and Zevtera®) and three oncology drug candidates in clinical development. We are building on our potential for sustainable growth and valuation generation, based on increasing revenues and selective investments into internal and external innovation. Basilea was founded in 2000 and is located in the life sciences hub of the Basel area. Basilea has about 150 employees. Since 2004, Basilea is listed on the SIX Swiss Stock Exchange with the ticker symbol BSLN.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-02-18 01:00 |
Earnings Release
Basilea reports strong 2024 full-year results with significant increase in reve…
|
English | 19.9 KB | |
| 2025-02-18 01:00 |
Earnings Release
Basilea meldet für das Gesamtjahr 2024 ein starkes Ergebnis mit deutlichem Anst…
|
German | 23.1 KB | |
| 2024-12-23 01:00 |
Regulatory News Service
Basilea is awarded additional CARB-X funding to develop new drug candidate from…
|
English | 7.8 KB | |
| 2024-12-23 01:00 |
Regulatory News Service
Basilea erhält zusätzliche CARB-X-Förderung für die Entwicklung eines Medikamen…
|
German | 9.2 KB | |
| 2024-12-16 01:00 |
Regulatory News Service
Basilea announces agreement with Innoviva Specialty Therapeutics for the commer…
|
English | 9.4 KB | |
| 2024-12-16 01:00 |
Regulatory News Service
Basilea gibt Vereinbarung mit Innoviva Specialty Therapeutics zur Vermarktung v…
|
German | 11.1 KB | |
| 2024-09-19 02:00 |
Capital/Financing Update
Basilea enters into agreement with BARDA to develop novel antifungals and antib…
|
English | 13.7 KB | |
| 2024-09-19 02:00 |
Capital/Financing Update
Basilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente…
|
German | 15.7 KB | |
| 2024-09-06 02:00 |
Earnings Release
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 mi…
|
English | 6.4 KB | |
| 2024-09-06 02:00 |
Earnings Release
Starke Cresemba® (Isavuconazol)-Verkäufe in Europa lösen USD 25 Mio. Umsatzmeil…
|
German | 7.5 KB | |
| 2024-08-27 02:00 |
Regulatory News Service
European Commission Decision to approve the pediatric use of antifungal Cresemb…
|
English | 7.1 KB | |
| 2024-08-27 02:00 |
Regulatory News Service
Entscheidung der Europäischen Kommission zur Zulassung von Antipilzmittel Crese…
|
German | 8.1 KB | |
| 2024-08-13 02:00 |
Earnings Release
Basilea reports strong 2024 half-year results and significantly increases full-…
|
English | 17.7 KB | |
| 2024-08-13 02:00 |
Earnings Release
Basilea meldet starke Halbjahresergebnisse 2024 und erhöht signifikant den Ausb…
|
German | 19.6 KB | |
| 2024-04-04 02:00 |
Regulatory News Service
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocari…
|
English | 15.3 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-21 | N/A | Executive member | Sell | None | 27,000.00 CHF |
| 2025-04-30 | N/A | Executive member | Sell | None | 17,600.00 CHF |
| 2025-04-23 | N/A | Executive member | Sell | None | 57,396.20 CHF |
| 2025-04-23 | N/A | Non-Executive member | Sell | None | 30,331.00 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 173,479.91 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 118,568.67 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 41,255.63 CHF |
| 2024-10-28 | N/A | Executive member | Sell | None | 22,500.00 CHF |
| 2024-04-25 | N/A | Executive member | Sell | None | 79,966.26 CHF |
| 2024-04-24 | N/A | Executive member | Sell | None | 23,128.70 CHF |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Hamlet BioPharma AB | Sweden | HAMLET | |
|
Harm Reduction Group AB | Sweden | NOHARM | |
|
Heidelberg Pharma AG | Germany | HPHA | |
|
HELLENIC DYNAMICS PLC | United Kingdom | HELD | |
|
HIKMA Pharmaceuticals PLC | United Kingdom | HIK | |
|
H. Lundbeck A | Denmark | HLUN | |
|
Hod-Assaf Industries Ltd. | Israel | HOD | |
|
HUDDLED GROUP PLC | United Kingdom | HUD | |
|
Iconovo AB | Sweden | ICO | |
|
iDNA Genomics Public Ltd | Cyprus | IDNA |